title: Comparison of vasopeptidase inhibitor omapatrilat and angiotensin receptor blocker candesartan on extracellular matrix, myeloperoxidase, cytokines, and ventricular remodeling during healing after reperfused myocardial infarction.
abstract: We determined effects of the vasopeptidase inhibitor (VPI) omapatrilat and angiotensin II type 1 receptor (AT(1)R) blocker (ARB) candesartan in rats during healing between day-2 and day-21 after reperfused myocardial infarction (RMI) on left ventricular (LV) remodeling and function, and regional matrix metalloproteinase (MMP)-9, tissue inhibitor of MMP (TIMP)-3, inducible-nitric-oxide-synthase (iNOS), oxidant-generating myeloperoxidase (MPO), and cytokines tumor-necrosis-factor (TNF)-alpha, interleukin (IL)-6 and IL-10, and transforming-growth-factor (TGF)-beta(1), and collagens. Compared to RMI-placebo, both agents reversed adverse LV remodeling and systolic and diastolic dysfunction, improved collagen remodeling, and normalized MMP-9 (activity, protein, and mRNA), TIMP-3 (protein and mRNA), and iNOS, MPO, TNF-alpha, IL-6, and TGF-beta(1) proteins, and improved MMP-9/TIMP-3 balance and IL-10 levels in previously ischemic zones. The results suggest that modulation of matrix proteases, oxidants, cytokines, and NOSs with omapatrilat and candesartan contribute to reversal of adverse collagen and LV remodeling and attenuation of LV dysfunction during healing after RMI.
authors.affiliation: Cardiovascular Research Group, Faculty of Medicine, University of Alberta, AB, Canada.
authors.forename: Arivazhagan
authors.initials: A
authors.lastname: Palaniyappan
authors.forename: Richard R E
authors.initials: RR
authors.lastname: Uwiera
authors.forename: Halliday
authors.initials: H
authors.lastname: Idikio
authors.forename: Bodh I
authors.initials: BI
authors.lastname: Jugdutt
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology*; D000818:Animals; D001562:Benzimidazoles / Q000494:pharmacology*; D001713:Biphenyl Compounds; D002317:Cardiovascular Agents / Q000494:pharmacology; D016207:Cytokines / Q000378:metabolism*; D005109:Extracellular Matrix / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D007527:Isoenzymes / Q000235:genetics / Q000378:metabolism; D020778:Matrix Metalloproteinase 2 / Q000235:genetics / Q000378:metabolism; D020780:Matrix Metalloproteinase 9 / Q000235:genetics / Q000378:metabolism; D015425:Myocardial Reperfusion; D009206:Myocardium / Q000378:metabolism / Q000473:pathology; D019001:Nitric Oxide Synthase / Q000235:genetics / Q000378:metabolism; D009195:Peroxidase / Q000378:metabolism*; D011480:Protease Inhibitors / Q000494:pharmacology*; D011725:Pyridines / Q000494:pharmacology*; D011897:Random Allocation; D051381:Rats; D013777:Tetrazoles / Q000494:pharmacology*; D013841:Thiazepines / Q000494:pharmacology*; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000235:genetics / Q000378:metabolism; D019717:Tissue Inhibitor of Metalloproteinase-3 / Q000235:genetics / Q000378:metabolism; D020257:Ventricular Remodeling / Q000187:drug effects* / Q000502:physiology
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D002317:Cardiovascular Agents; D016207:Cytokines; D007527:Isoenzymes; D011480:Protease Inhibitors; D011725:Pyridines; D013777:Tetrazoles; D013841:Thiazepines; D019715:Tissue Inhibitor of Metalloproteinase-1; D019717:Tissue Inhibitor of Metalloproteinase-3; C106266:omapatrilat; D009195:Peroxidase; D019001:Nitric Oxide Synthase; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9; C081643:candesartan
references.citation: Circulation. 2003 Dec 9;108(23):2911-7
references.pmid: 14656914
references.citation: J Card Fail. 2004 Oct;10(5):442-9
references.pmid: 15470656
references.citation: J Am Soc Echocardiogr. 2004 Feb;17(2):161-7
references.pmid: 14752491
references.citation: Mol Cell Biochem. 2007 Sep;303(1-2):27-38
references.pmid: 17426929
references.citation: Circulation. 2002 Aug 20;106(8):920-6
references.pmid: 12186794
references.citation: J Card Fail. 2004 Feb;10(1):83-9
references.pmid: 14966779
references.citation: Am J Hypertens. 1999 Feb;12(2 Pt 1):174-82
references.pmid: 10090345
references.citation: Cardiovasc Res. 1997 Feb;33(2):422-32
references.pmid: 9074708
references.citation: J Pharmacol Methods. 1985 Nov;14(3):157-67
references.pmid: 2997548
references.citation: J Hypertens Suppl. 1999 Feb;17(1):S37-43
references.pmid: 10340842
references.citation: Circulation. 1998 Mar 3;97(8):795-804
references.pmid: 9498544
references.citation: Hypertension. 2000 Dec;36(6):1105-11
references.pmid: 11116133
references.citation: Circulation. 2003 Sep 16;108(11):1395-403
references.pmid: 12975244
references.citation: Lancet. 2000 Aug 19;356(9230):615-20
references.pmid: 10968433
references.citation: Heart Fail Rev. 2002 Oct;7(4):407-22
references.pmid: 12379825
references.citation: Circulation. 2005 Nov 1;112(18):2812-20
references.pmid: 16267254
references.citation: Vasc Health Risk Manag. 2006;2(2):125-38
references.pmid: 17319456
references.citation: Biol Reprod. 2006 Jan;74(1):13-22
references.pmid: 16135696
references.citation: Circulation. 1995 Aug 15;92(4):926-34
references.pmid: 7641376
references.citation: Curr Drug Targets Cardiovasc Haematol Disord. 2003 Mar;3(1):1-30
references.pmid: 12769643
references.citation: Cardiovasc Res. 2002 Jan;53(1):31-47
references.pmid: 11744011
references.citation: J Card Fail. 2006 Feb;12(1):73-6
references.pmid: 16500584
references.citation: J Cardiovasc Pharmacol. 1998 Jan;31(1):116-25
references.pmid: 9456286
references.citation: Am Heart J. 2005 Aug;150(2):257-62
references.pmid: 16086927
references.citation: Proteomics. 2007 Jun;7(12):2100-10
references.pmid: 17514685
references.citation: J Card Fail. 2004 Feb;10(1):74-82
references.pmid: 14966778
references.citation: Ann Allergy Asthma Immunol. 2008 Apr;100(4):327-32
references.pmid: 18450117
references.citation: Circulation. 1996 Jul 1;94(1):94-101
references.pmid: 8964124
references.citation: J Cardiovasc Pharmacol. 1999 Dec;34(6):782-90
references.pmid: 10598120
references.citation: Mol Cell Biochem. 2004 Jul;262(1-2):203-14
references.pmid: 15532725
references.citation: Circulation. 2002 Oct 29;106(18):2351-7
references.pmid: 12403666
references.citation: J Am Coll Cardiol. 2002 May 15;39(10):1692-8
references.pmid: 12020499
references.citation: Heart Fail Rev. 2002 Oct;7(4):391-405
references.pmid: 12379824
references.citation: Circulation. 2003 Apr 15;107(14):1923-9
references.pmid: 12668518
references.citation: J Pharmacol Exp Ther. 1999 Feb;288(2):742-51
references.pmid: 9918584
references.citation: Lancet. 2003 Sep 6;362(9386):772-6
references.pmid: 13678870